Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...

Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC: New York Monday, September 16, 2024, 10:00 Hrs [IST ...

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

A summary of current health news, including a Nipah virus death in Kerala, an mpox case rise in Uganda, and Pfizer's efforts ...

KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi ...

(RTTNews) - Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI (encorafenib) in combination ...

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...